Physician profile
Emma Lanuti
NPI 1710118534
$4,389.55
in general payments reported to CMS, 2019-2025
29 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $67.81 · 2022: $687 · 2023: $888 · 2024: $1,395 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,206 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,206.15 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,127.72 | 2022-2025 | Tremfya |
| Abbvie INC. | $704.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $279.25 | 2023-2025 | |
| Lilly USA, LLC | $210.83 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $189.72 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $180.40 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.43 | 2024-2025 | Spevigo |
| Genzyme Corporation | $170.96 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $164.44 | 2022-2025 | Blu-U, Odomzo |
| E.R. Squibb & Sons, L.L.C. | $162.21 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $145.73 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Pfizer INC. | $107.40 | 2019-2025 | |
| Leo Pharma INC. | $103.72 | 2019-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $98.80 | 2022-2024 | Vtama |
| Celgene Corporation | $91.02 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $77.63 | 2024 | Bimzelx |
| Strata Skin Sciences, INC. | $77.19 | 2023 | Xtrac |
| Amgen INC. | $53.13 | 2024-2025 | Otezla |
| Almirall LLC | $44.53 | 2022-2025 | Klisyri |
| Nabriva Therapeutics, Plc | $42.15 | 2022 | |
| Biofrontera INC. | $35.15 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $24.09 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $20.77 | 2022 | |
| Vyne Pharmaceuticals INC. | $20.63 | 2020 | |
| Glaxosmithkline, LLC. | $20.22 | 2023 | Arexvy, Shingrix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.19 | 2019 | |
| Arcutis Biotherapeutics, INC. | $17.28 | 2024 | Zoryve |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Dusa Pharmaceuticals, INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Lanuti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.